Status and phase
Conditions
Treatments
Study type
Funder types
Identifiers
About
The main purpose of this study is to determine the tolerability and side effects related to LY3875383 given as a single injection under the skin to healthy participants and participants with elevated triglyceride (TG) levels.The study will also assess how fast LY3875383 gets into the blood stream and how long the body takes to get rid of it. Each enrolled participant will receive a single dose of either LY3875383 or placebo.The study will be conducted in four parts (A, B, C and D) and may last up to approximately 28 to 56 weeks including screening.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
All participants:
Healthy participants (Part A):
• Participants must be overtly healthy, as determined by medical evaluation.
For Part B:
• Participants must be first-generation Japanese, defined as the participant's biological parents, and all of the participant's biological grandparents must be of exclusive Japanese descent and born in Japan.
Hypertriglyceridemia participants (Parts C and D):
For Part C:
For Part D:
Exclusion criteria
All participants:
For Part C: Have active pancreatitis within the last 6 months
Primary purpose
Allocation
Interventional model
Masking
41 participants in 8 patient groups, including a placebo group
Loading...
Central trial contact
There may be multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285-4559) or
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal